

Market Round-up

V37 – 5th July, 2019

Drug Approvals/Filings:

- **GSK's** investee company, **ViiV Healthcare**, has received EC marketing authorisation for *Dovato*, which treats HIV-1 in adults and adolescents.
[LINK](#)
- NICE has backed the use of **Pfizer's** EGFR inhibitor *Vizimpro* for NHS use.
[LINK](#)
- NICE backs CDF funding for **Sanofi/Regeneron's** skin cancer drug *Libtayo*
[LINK](#)
- **Gilead** to file for US approval of *filgotinib's* treatment of RA this year.
[LINK](#)
- FDA approves **Pfizer's** oncology mAb biosimilar *Zirabev*
[LINK](#)
- **AstraZeneca** has announced that the European Medicines Agency's CHMP has approved a label expansion of its diabetes drug *Forxiga* and respiratory drug *Fasenra*.
[LINK](#)

Biosimilars/Biologics:

- **Mundipharma** partners with **Prestige** to commercialise and supply a biosimilar to **Roche's** *Herceptin*, for patients with breast, gastric and gastroesophageal cancer.
[LINK](#)
- Global Biosimilars market is estimated to grow at a CAGR of +6% by 2025. The top companies include **Pfizer**, **Sandoz**, **Teva Pharmaceuticals** and **Amgen**.
[LINK](#)

Mergers & Acquisitions:

- **AbbVie** entered into an agreement to acquire **Allergan** for \$63 billion or \$188 a share in cash and stock.
[LINK](#)
- **Biotech** braces for busy summer as 2019 **Mergers & Acquisitions** volume heats up
[LINK](#)
- **Novartis** acquired ophthalmic drug *Xiidra* from **Takeda** for \$3.4bn. *Xiidra* is the first prescription medicine to be approved for the treatment of dry eye disease symptoms.
[LINK](#)
- **LEO Pharma** has completed the acquisition of **Bayer's** dermatology business
[LINK](#)
- **Perrigo** has completed the acquisition of privately-held **Ranir Global Holdings** - the global leader in private label oral self-care products.
[LINK](#)

NCPE *Drug Updates*

- **No updates this week.**
-

General Market News:

- **GSK** launches Phase III programme of rheumatoid arthritis (RA) drug *Otilimab*
[LINK](#)
- Two NGOs have filed an objection with the European patent office in Munich challenging the patent protection of **Novartis's** drug *Kymriah*.
[LINK](#)
- **Mylan** and **Sanofi** both seek summary judgment in EpiPen suit.
[LINK](#)